A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of KQB198 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hematologic Malignancies
Latest Information Update: 30 Mar 2026
At a glance
- Drugs Dasatinib (Primary) ; KQB 198 (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kumquat Biosciences
Most Recent Events
- 25 Mar 2026 Planned End Date changed from 1 Feb 2028 to 1 Mar 2027.
- 25 Mar 2026 Planned primary completion date changed from 1 Aug 2027 to 1 Mar 2027.
- 25 Mar 2026 Status changed from recruiting to active, no longer recruiting.